9 Meters Biopharma, Inc. (NMTR) |
|
1.3471 0.037 (2.83%)
|
03-22 12:54 |
|
Open: |
1.32 |
Pre. Close: |
1.31 |
|
High:
|
1.36 |
Low:
|
1.3 |
|
Volume:
|
20,143 |
Market Cap:
|
19(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 12:48:49 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.22 One year: 2.66 |
| Support: |
Support1: 1.28 Support2: 1.07 |
| Resistance: |
Resistance1: 1.9 Resistance2: 2.27 |
| Pivot: |
1.48  |
| Moving Average: |
MA(5): 1.34 MA(20): 1.54
MA(100): 1.86 MA(250): 4.75 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 5.6 %D(3): 6.9 |
| RSI: |
RSI(14): 33.3 |
| 52-week: |
High: 13.19 Low: 0.22 |
| Average Vol(K): |
3-Month: 111 (K) 10-Days: 95 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NMTR ] has closed above bottom band by 20.7%. Bollinger Bands are 45.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.36 - 1.37 |
1.37 - 1.38 |
|
Low:
|
1.28 - 1.29 |
1.29 - 1.3 |
|
Close:
|
1.29 - 1.31 |
1.31 - 1.33 |
|
Company Description |
|
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina. |
Headline News |
Wed, 15 Mar 2023
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Tue, 07 Mar 2023
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual ... - Digital Journal
Tue, 14 Feb 2023
Citigroup Initiates Coverage of 9 Meters Biopharma (NMTR) with ... - Nasdaq
Tue, 31 Jan 2023
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor ... - AccessWire
Wed, 04 Jan 2023
How Will the Market React to 9 Meters Biopharma Inc (NMTR) Stock Getting a Bullish Rating - InvestorsObserver
Mon, 17 Oct 2022
9 Meters Biopharma Announces 1-for-20 Reverse Stock Split - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
13 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
19.1 (%) |
|
Shares Short
|
512 (K) |
|
Shares Short P.Month
|
380 (K) |
Stock Financials |
|
EPS
|
-0.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.18 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-51.2 |
|
Return on Equity (ttm)
|
-132 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.12 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-35 (M) |
|
Levered Free Cash Flow
|
-18 (M) |
Stock Valuations |
|
PE Ratio
|
-9.02 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.97 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
